IASLC专家小组综述:胸部恶性肿瘤免疫检查点抑制剂证据与推荐
IASLC国际专家小组综述胸部恶性肿瘤免疫检查点抑制剂(ICI)的现有证据并给出临床推荐。ICI单药、联合化疗及双免疫联合在晚期NSCLC取得突破性进展,SCLC获益较小,胸腺癌有令人鼓舞的活性,恶性胸膜间皮瘤的阳性信号尚未在随机试验中完全确认。专家小组还讨论了耐药、进展模式标准化、预测生物标志物、最佳治疗时长及特殊人群疗效等关键问题。
要点
- ICI单药、联合化疗及双免疫联合已为晚期NSCLC带来突破性治疗进展
- SCLC获益程度低于NSCLC,胸腺癌经治患者显示令人鼓舞的活性
- 恶性胸膜间皮瘤的关键阳性活性信号尚未在随机试验中完全确认
核心结论
- ICI在晚期NSCLC取得突破性治疗进展,在SCLC获益较小,在经治胸腺癌显示令人鼓舞的活性,在恶性胸膜间皮瘤的 pivotal 阳性活性信号尚未在随机试验中完全确认。
- 原发性和获得性耐药是已知生物学现象,可能影响ICI疗效,需创新策略克服耐药并回答关键问题以改善胸部恶性肿瘤患者的治疗获益。
研究设计与样本
- IASLC国际专家小组对胸部恶性肿瘤领域现有科学证据进行综述,并据此提供临床推荐以指导当前实践和未来治疗策略与研究重点。
主要发现
- 程序性细胞死亡蛋白1/程序性死亡配体-1免疫检查点抑制剂单药及联合化疗,以及近期ICI联合抗程序性细胞死亡蛋白1与抗细胞毒性T淋巴细胞相关抗原4抗体的策略,为晚期NSCLC患者带来突破性治疗进展,SCLC患者获益程度较小。
- 经治胸腺癌患者近期显示令人鼓舞的活性;恶性胸膜间皮瘤的关键阳性活性信号尚未在随机试验中完全确认。
- 化疗放疗与免疫治疗的叠加效应提示联合策略具有治疗协同潜力,已推动III期NSCLC引入ICI巩固治疗,并为早期疾病未来治疗发展创建平台。
临床怎么用
- 专家小组基于现有证据提供临床推荐,以指导肿瘤内科医生在当前实践中使用ICI治疗胸部恶性肿瘤。
- ICI巩固治疗已引入III期NSCLC,并为早期疾病未来治疗发展创建平台。
局限性
- 原发性和获得性耐药可能影响ICI疗效。
- ICI耐药创新策略、ICI进展新模式标准化、应答预测生物标志物、最佳治疗时长及特殊人群ICI疗效表征等关键问题尚待充分解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class of agents. The reactivation of host antitumor immune response offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies. The advent of programmed cell death protein 1/programmed death ligand-1 immune checkpoint inhibitors (ICIs), both as single agents and in combination with chemotherapy, and more recently, the combination of ICI, anti-programmed cell death protein 1, and anticytotoxic T-lymphocyte antigen 4 antibody, have led to breakthrough therapeutic advances for patients with advanced NSCLC, and to a lesser extent, patients with SCLC. Encouraging activity has recently emerged in pretreated patients with thymic carcinoma (TC). Conversely, in malignant pleural mesothelioma, pivotal positive signs of activity have not been fully confirmed in randomized trials. The additive effects of chemoradiation and immunotherapy suggested intriguing potential for therapeutic synergy with combination strategies. This has led to the introduction of ICI consolidation therapy in stage III NSCLC, creating a platform for future therapeutic developments in earlier-stage disease. Despite the definitive clinical benefit observed with ICI, primary and acquired resistance represent well-known biological phenomena, which may affect the therapeutic efficacy of these agents. The development of innovative strategies to overcome ICI resistance, standardization of new patterns of ICI progression, identification of predictive biomarkers of response, optimal treatment duration, and characterization of ICI efficacy in special populations, represent crucial issues to be adequately addressed, with the aim of improving the therapeutic benefit of ICI in patients with thoracic malignancies. In this article, an international panel of experts in the field of thoracic malignancies discussed these topics, evaluating currently available scientific evidence, with the final aim of providing clinical recommendations, which may guide oncologists in their current practice and elucidate future treatment strategies and research priorities.
引用
- Remon J, Passiglia F, Ahn MJ, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol. 2020. PMID: 32179179. doi:10.1016/j.jtho.2020.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。